On the contrary, activated DCs are converted into tolerogenic phenotypes in the tumour microenvironment, where they promote Tregs (and not T‐effector cells), with the production of TGFβ and IL‐10 as an escape mechanism from immune clearance.1, 2. The gene discussed is TGFB1; the disease is neoplasm.